Isosorbide Mononitrate Injection

Isosorbide mononitrate (ISMN) is the main biologically active metabolite of isosorbide dinitrate. Like other organic nitrates, its main pharmacological action is to relax vascular smooth muscle. ISMN releases nitric oxide (NO). NO is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Venous dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart, and reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation reduces peripheral vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Coronary artery dilation increases coronary perfusion. The overall effect is to reduce myocardial oxygen consumption, increase oxygen supply, and relieve angina pectoris. No carcinogenic and mutagenic phenomena were observed in animal experiments.

The main ingredient of this product is isosorbide mononitrate. Chemical name: 1,4:3,6-dianhydro-D-sorbitol-5-mononitrate. Molecular formula: C6H9NO6. Molecular weight: 191.14.

Long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; combined with digitalis and/or diuretics to treat chronic congestive heart failure.

After diluting with 5% glucose injection, start intravenous drip at 1~2mg/hr, and adjust the dose according to the patient's response. The maximum dose is 8~10mg. The patient's heart rate and blood pressure must be closely observed during medication. Due to different individual responses, the dose needs to be adjusted individually.

Nitrate-induced vasodilatory headaches may occur in the early stages of medication, but usually disappear after a few days of continuous use. Facial flushing, dizziness, orthostatic hypotension, and reflex tachycardia may also occur. Occasionally, blood pressure may drop significantly, bradycardia, aggravated angina pectoris, and syncope may occur.

Acute circulatory failure (shock, circulatory collapse); severe hypotension (systolic blood pressure 90 mmHg); acute myocardial infarction with low filling pressures (unless under continuous hemodynamic monitoring); hypertrophic obstructive cardiomyopathy; constrictive pericarditis or cardiac tamponade; severe anaemia; glaucoma; increased intracranial pressure; allergy to nitro compounds.

Combination with other vasodilators, calcium antagonists, beta-receptor blockers, antihypertensive drugs, tricyclic antidepressants and alcohol can enhance the blood pressure lowering effect of this class of drugs.

Keep away from light and sealed. Validity period: tentatively two years.

5ml:20mg

Yiling Pharmaceutical Ltd.

• Founded in:

  2014-07-28

• Address:

  No. 36, Zhujiang Avenue, Shijiazhuang High-tech Zone

• Tax NO.:

  911301013989550179

• Registered Funds:

  675 million yuan

• Website:

  Log in to view

• Email:

  Log in to view